Variation in the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features

Noninvasive encapsulated follicular variant of papillary thyroid cancer was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in January 2017. The impact of this nomenclature change at a population level remains unknown. Examine use of NIFTP across...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2022-09, Vol.107 (10), p.e4072-e4077
Main Authors: Chen, Debbie W, Rob, Farizah I, Mukherjee, Rik, Giordano, Thomas J, Haymart, Megan R, Banerjee, Mousumi
Format: Article
Language:English
Subjects:
Adenocarcinoma, Follicular - diagnosis
Adenocarcinoma, Follicular - epidemiology
Adenocarcinoma, Follicular - pathology
Analysis
Biopsy, Fine-Needle
Epidemiology
Health aspects
Humans
Online Only
Thyroid cancer
Thyroid Cancer, Papillary - diagnosis
Thyroid Cancer, Papillary - epidemiology
Thyroid Cancer, Papillary - pathology
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - epidemiology
Thyroid Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Noninvasive encapsulated follicular variant of papillary thyroid cancer was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in January 2017. The impact of this nomenclature change at a population level remains unknown. Examine use of NIFTP across different US regions and populations. Descriptive epidemiology study using SEER-22 data (2000-2019). Individuals diagnosed with papillary or follicular thyroid cancer (2000-2019) or NIFTP (2017-2019). Annual incidence rates of thyroid cancer by subtype and NIFTP. Using 2018-2019 data, (1) rates of NIFTP at the 17 SEER-22 sites and (2) comparison of demographics for patients diagnosed with NIFTP vs papillary and follicular thyroid cancer. NIFTP comprised 2.2% and 2.6% of cases in 2018 and 2019, respectively. Between 2018 and 2019, large heterogeneity was observed in the regional use of NIFTP diagnosis, with site-specific incidence rates between 0.0% and 6.2% (median 2.8%, interquartile range 1.3-3.6%). A diagnosis of NIFTP (vs papillary and follicular thyroid cancer) in 2018 and 2019 was significantly associated with older age (P = 0.012 and P = 0.009, respectively), Black race (both Ps 
ISSN:0021-972X
1945-7197
DOI:10.1210/clinem/dgac466